[The therapeutic use of pulmonary surfactant in neonatal hyaline membrane disease].
Preliminary report of our experience with the therapeutic use of pulmonary surfactant in newborn infants of less than 30 weeks gestation with hyaline membrane disease. The use of pulmonary surfactant was held under the "rescue" modality, with up to 36 hours of postnatal life. The blood gas changes are described and the assisted ventilation progress, as well as the general response on the clinical condition of each case. Discussion in centered in the risk of use and in the criteria for prescribing the therapeutic pulmonary surfactant. It is concluded that meeting the recommended requirements for its use, the pulmonary surfactant is a therapeutic alternative in the treatment of hyaline membrane disease in newborn infants of less than 33 weeks gestation, being different the immediate ventilatory response in terms of therapeutic control, with one or other forms of pulmonary exogenous surfactant, without differences in the final result.
Lozano-González
C H
CH
Departamento de Neonatología y Medicina Perinatal Pediátrica, Centro de Ginecología y Obstetricia de Monterrey, N. L., México.
Piña-Ceballos
V M
VM
Beyer-Obezo
J
J
Gutiérrez-Martín
A
A
Martínez-Hinojosa
B
B
Flores-Támez
M E
ME
D001784:Blood Gas Analysis; D004341:Drug Evaluation; D005865:Gestational Age; D006801:Humans; D006819:Hyaline Membrane Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007442:Intubation, Intratracheal; D008297:Male; D011187:Posture; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D012119:Respiration / Q000187:drug effects
D011663:Pulmonary Surfactants
Uso terapéutico del surfactante pulmonar en la enfermedad de membrana hialina neonatal.